Cramer Rosenthal Mcglynn LLC Has $80.27 Million Holdings in Steris Plc (STE)
Cramer Rosenthal Mcglynn LLC lessened its holdings in Steris Plc (NYSE:STE) by 26.9% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 908,062 shares of the medical equipment provider’s stock after selling 333,585 shares during the period. Steris makes up approximately 1.3% of Cramer Rosenthal Mcglynn LLC’s portfolio, making the stock its 20th biggest holding. Cramer Rosenthal Mcglynn LLC owned 1.07% of Steris worth $80,273,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also made changes to their positions in STE. Janus Henderson Group PLC boosted its stake in shares of Steris by 1,972.4% in the 2nd quarter. Janus Henderson Group PLC now owns 7,679,507 shares of the medical equipment provider’s stock worth $625,880,000 after buying an additional 7,308,950 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Steris by 33.4% in the 2nd quarter. BlackRock Inc. now owns 7,032,984 shares of the medical equipment provider’s stock worth $573,188,000 after buying an additional 1,760,879 shares during the last quarter. Koch Industries Inc. purchased a new position in shares of Steris in the 2nd quarter worth approximately $1,089,000. Principal Financial Group Inc. boosted its stake in shares of Steris by 115.1% in the 2nd quarter. Principal Financial Group Inc. now owns 1,911,958 shares of the medical equipment provider’s stock worth $155,825,000 after buying an additional 1,023,035 shares during the last quarter. Finally, FMR LLC boosted its stake in shares of Steris by 33.1% in the 2nd quarter. FMR LLC now owns 3,454,533 shares of the medical equipment provider’s stock worth $281,544,000 after buying an additional 859,228 shares during the last quarter. Hedge funds and other institutional investors own 89.45% of the company’s stock.
Steris Plc (STE) traded down $0.31 during trading hours on Monday, hitting $89.65. 243,000 shares of the company were exchanged, compared to its average volume of 461,173. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.80 and a quick ratio of 2.18. The company has a market cap of $7,624.94, a PE ratio of 23.11 and a beta of 1.27. Steris Plc has a 52 week low of $64.46 and a 52 week high of $93.39.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 20th. Investors of record on Wednesday, November 22nd will be issued a $0.31 dividend. The ex-dividend date of this dividend is Tuesday, November 21st. This represents a $1.24 dividend on an annualized basis and a dividend yield of 1.38%. Steris’s dividend payout ratio (DPR) is presently 73.81%.
In other Steris news, VP John Adam Zangerle sold 3,650 shares of the business’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $88.00, for a total transaction of $321,200.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Walter M. Rosebrough, Jr. sold 10,000 shares of the business’s stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $90.50, for a total transaction of $905,000.00. The disclosure for this sale can be found here. Insiders sold a total of 192,722 shares of company stock worth $16,913,753 in the last ninety days. 2.55% of the stock is currently owned by insiders.
A number of equities research analysts recently commented on the stock. KeyCorp reaffirmed an “overweight” rating and issued a $101.00 price target (up previously from $91.00) on shares of Steris in a report on Thursday, November 2nd. Zacks Investment Research cut shares of Steris from a “buy” rating to a “sell” rating in a report on Monday, November 6th. TD Securities lifted their price target on shares of Steris from C$14.00 to C$16.00 and gave the stock a “buy” rating in a report on Thursday, November 9th. Finally, Raymond James Financial lifted their price target on shares of Steris from $90.00 to $95.00 and gave the stock an “outperform” rating in a report on Wednesday, August 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $79.50.
ILLEGAL ACTIVITY WARNING: This piece was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/04/cramer-rosenthal-mcglynn-llc-has-80-27-million-holdings-in-steris-plc-ste.html.
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
Receive News & Stock Ratings for Steris Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris Plc and related stocks with our FREE daily email newsletter.